Chugai Press Release

09/14/2018 - 06:21 Chugai Selected for the Fourth Time for Dow Jones Sustainability Asia Pacific Index
08/30/2018 - 14:34 Results of Global Phase III Study with Chugai's HEMLIBRA for Hemophilia A without Inhibitors Published in the New England Journal of Medicine
08/29/2018 - 13:36 Chugai Obtains Platinum Kurumin Certification from the Minister of Health, Labour and Welfare as a Company Supporting Childrearing
08/29/2018 - 13:30 Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody "GAZYVA "
08/02/2018 - 20:02 Anti-CD20 Monoclonal Antibody RITUXAN , Application for Approval of Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
07/26/2018 - 12:02 Chugai Pharmabody Research Pte. Ltd., Chugais Research Subsidiary
07/26/2018 - 10:51 Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APls
07/17/2018 - 00:57 Chugai to In-license ROS1/TRK Inhibitor Entrectinib
07/02/2018 - 12:20 Humanized Anti-CD20 Monoclonal Antibody, GAZYVA Intravenous Infusion 1000 mg, Approved for the Treatment of CD20-Positive Follicular Lymphoma
06/05/2018 - 11:20 Chugais HEMLIBRA Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors
05/28/2018 - 19:52 Humanized Anti-Human IL-6 Receptor Monoclonal Antibody ACTEMRA , Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy
05/24/2018 - 01:29 Humanized Anti-Human IL-6 Receptor Monoclonal Antibody ACTEMRA , Application for Approval of Additional Indication of Adult Onset Still's Disease
05/21/2018 - 23:50 Launch of HEMLIBRA Subcutaneous Injection for the Treatment of Hemophilia A
05/20/2018 - 22:22 Chugai Presents Results of Two Pivotal Phase III Studies
05/15/2018 - 23:31 Chugais ALK Inhibitor Alecensa Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan
05/09/2018 - 23:40 Chugais Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab, Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
04/26/2018 - 02:01 Chugai Files Applications for HEMLIBRA for the Treatment of Hemophilia A without Factor VIII Inhibitors and for Extension of Dosing Interval
04/20/2018 - 00:23 Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
04/17/2018 - 22:10 Launch of the Anti-Cancer Agent / a Humanized Anti-PD-L1 Monoclonal Antibody TECENTRIQ
04/11/2018 - 02:19 Waiver of Claims in Patent Infringement Lawsuit
03/23/2018 - 02:10 Anti-Coagulation Factor IXa/X Humanized Bispecific Monoclonal Antibody HEMLIBRA Subcutaneous Injection Approved in Japan
03/21/2018 - 21:40 New Drug Application of Eldecalcitol, an Active Vitamin D 3 Derivative, for the Treatment of Osteoporosis Accepted in China
03/21/2018 - 19:38 Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
03/20/2018 - 00:45 Injection Syringe 12.5g Approved in Japan
03/16/2018 - 00:57 Chugai Starts Activities towards Commercialization of
01/31/2018 - 20:59 Further Improving Access to Therapies for Non-Small Cell Lung Cancer
01/19/2018 - 03:13 Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, TECENTRIQ
12/25/2017 - 20:52 The Launch of Chugais New Corporate Advertisement
12/20/2017 - 23:29 EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
12/17/2017 - 23:16 Launch of the Photodynamic Diagnostic Agent "ALAGLIO Divided Granules 1.5g"
12/11/2017 - 01:24 Atezolizumab plus Avastin Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study
12/07/2017 - 03:45 Chugais Emicizumab Every Four Weeks Showed Positive Interim Results
11/29/2017 - 03:33 TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for gMSC
11/21/2017 - 04:16 Immune Checkpoint Inhibitor Atezolizumab Significantly Improves Progression Free Survival in Patients with Non-Small Cell Lung Cancer Compared with Chemotherapy in the IMpower150 Study
11/20/2017 - 00:45 Meets Primary Endpoint in Phase III Study
11/13/2017 - 23:56 Notice Concerning Execution of Asset Transfer of 13 Long-Term Listed Products from Chugai to Taiyo Pharma
11/08/2017 - 05:55 Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
11/07/2017 - 04:13 "AYAs Life," a Website for Young Cancer Patients and Their Families, Undergoes Major Upgrade
11/06/2017 - 00:15 Eldecalcitol, an Active Vitamin D 3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study
11/01/2017 - 22:03 New Data of Emicizumab Presented
10/25/2017 - 03:29 Filed for Additional Indication of Adjuvant Therapy for HER2-Positive Early Breast Cancer
10/04/2017 - 21:23 Results of Preclinical Study Published in Science Translational Medicine
09/27/2017 - 00:05 Divided Granules 1.5g," a Photodynamic Diagnostic Agent Obtained Manufacture and Marketing Approval
08/25/2017 - 00:07 Both are Designated Intractable Diseases
08/24/2017 - 00:52 Chugais Emicizumab Receives Priority Review Designation by FDA
08/22/2017 - 21:27 New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab
07/31/2017 - 12:23 Chugai and National Cancer Center Japan
07/27/2017 - 17:25 Judgment Rendered on the Suit for Damages with Regard to the Process Patent Infringement for OXAROL Ointment
06/29/2017 - 03:12 Chugais Deputy Chairman Motoo Ueno as
06/27/2017 - 02:46 Chugai to Sponsor 2017 Wheelchair Softball Tournament in Tokyo
06/26/2017 - 02:35 Chugais Bispecific Antibody Emicizumab to Present
06/26/2017 - 02:27 Approval of Additional Dosage for Actemra
06/07/2017 - 01:51 Marketing and Manufacturing Right Transfer of 13 Long-Term Listed Products
06/06/2017 - 02:10 Data of Chugai's Alecensa Presented at the American Society of Clinical Oncology on Global Phase III ALEX Study
06/01/2017 - 02:10 Contribution of Funds to the Second Phase of
05/11/2017 - 01:58 Results of the J-ALEX Study for Chugai's Alecensa are Published in The Lancet Online
05/10/2017 - 02:20 Update on Phase III study of Immune Checkpoint Inhibitor
05/10/2017 - 02:08 Chugai Enters into a License Agreement for Emicizumab with JW Pharmaceutical
05/04/2017 - 04:09 Announcement of a Lawsuit Filed against Chugai
04/30/2017 - 02:46 Notice regarding Issuance of New Shares as Restricted Stock Compensation Plan
04/10/2017 - 03:11 Met Its Primary Endpoint in the ALEX Study
04/05/2017 - 04:05 - For the Future of Generation AYA Living with Cancer -
04/04/2017 - 03:52 A First Approach in the Japanese Pharmaceutical Industry
04/01/2017 - 02:25 Transfer of Rights to Insomnia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
03/30/2017 - 02:57 Chugai - A*STAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund
03/24/2017 - 02:39 The Supreme Court Rendered Favorable Judgment on Patent-Infringement Lawsuit Regarding OXAROL Ointment
03/24/2017 - 01:53 Anti-Influenza Drug, Tamiflu Dry Syrup 3%, Obtained Approval for Additional Dosage and Administration for Newborns and Infants
03/23/2017 - 02:10 Chugai Selected as a Nadeshiko Brand for the Third Consecutive Year
03/13/2017 - 02:30 SBI Pharma and Chugai Enter an Agreement of
03/02/2017 - 02:57 Chugais Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab (CIM331)
02/27/2017 - 03:45 Chugais ALK Inhibitor Alecensa
02/21/2017 - 03:28 - Alecensa is Available Now in Japan, the United States and Europe -
02/17/2017 - 04:18 New Drug Application Filed for Immune Checkpoint Inhibitor, Atezolizumab
02/01/2017 - 03:01 Notice regarding introduction of a Restricted Stock Compensation Plan
01/25/2017 - 05:06 Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services
12/22/2016 - 04:10 for the Treatment of Malignant Pleural Mesothelioma
12/22/2016 - 04:10 PharmaMar and Chugai Pharmaceutical Enter into
12/21/2016 - 23:42 Chugais Bispecific Antibody Emicizumab for Hemophilia A Meets Primary Endpoint in Phase lll Study
11/30/2016 - 04:38 Large Vessel Vasculitis, the Designated Intractable Disease
10/04/2016 - 22:39 Chugais ACTEMRA /RoACTEMRA Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis
10/04/2016 - 00:14 Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
09/28/2016 - 00:43 Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331),
09/13/2016 - 23:59 Chugai Selected for the Third Consecutive Year for Dow Jones Sustainability Asia Pacific Index
08/31/2016 - 23:26 Chugai Transfers the Manufacturing and Marketing Rights of VESANOID to Fuji Pharma
08/26/2016 - 00:58 Obtained Approval for Additional Indication of "Adjuvant Chemotherapy for Rectal Cancer"
08/26/2016 - 00:00 Chugai receives Orphan Drug Designation for Emicizumab
07/20/2016 - 23:57 Chugai and Galderma Announce Global License Agreement
06/21/2016 - 02:37 Chugai and Maruho Announce the Launch of
06/01/2016 - 06:10 Chugai Announces License Agreement for Recycling Antibody SA237
12/21/2015 - 09:40 Powder for Oral Suspension 31.8%”
12/14/2015 - 12:47 Accelerated Approval in Three Months after Priority Review Designation in the US
11/20/2015 - 16:28 Obtained Approval for Additional Indication of
11/09/2015 - 09:37 - License Agreement Expanded to Cover US and EU -
10/22/2015 - 04:12 Chugai to Newly Construct an Antibody API Manufacturing Plant
09/18/2015 - 21:50 Disclosure of Information on Chugai’s 2014 Corporate Activities
09/18/2015 - 21:02 NICE Recommends Chugai’s RoACTEMRA ® (tocilizumab) as Monotherapy for Treatment of Severe Rheumatoid Arthritis
09/17/2015 - 21:05 Application for Approval of Additional Indication of Recurrent/Advanced Cervical Cancer
09/16/2015 - 19:47 Chugai Selected for the Second Consecutive Year for the Dow Jones Sustainability Asia Pacific Index,
09/10/2015 - 09:49 Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo
09/09/2015 - 08:53 Chugai’s ALK Inhibitor “Alectinib,” New Drug Application
Copy and paste this code to display this page on your website .
Syndicate content